Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Net income was −$87M. Operating cash flow of −$80M less capital expenditure of $2M left free cash flow of −$82M.
Last 5 fiscal years
| Fiscal year | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Research & development | 28.5 | 57.4 | 79.2 |
| Operating income | −35.3 | −68.2 | −98.1 |
| Pre-tax income | – | −61.9 | −87.0 |
| Income tax | 0.0 | 0.0 | 0.0 |
| Net income | −32.6 | −61.9 | −87.0 |
| Diluted EPS | −31.96 | −5.82 | −2.38 |
| Diluted shares | 1.0 | 10.6 | 36.5 |
| Fiscal year | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Cash & equivalents | 30.5 | 49.4 | 75.3 |
| Current assets | 83.5 | 267 | 382 |
| Net PP&E | 0.4 | 1.1 | 2.7 |
| Total assets | 84.2 | 269 | 385 |
| Payables | 1.4 | 5.3 | 3.0 |
| Current liabilities | 3.9 | 11.1 | 15.5 |
| Total liabilities | 4.3 | 11.1 | 15.9 |
| Shareholders' equity | −72.5 | 257 | 369 |
| Fiscal year | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating cash flow | −32.0 | −54.7 | −79.9 |
| Capital expenditure | 0.1 | 0.9 | 1.9 |
| Free cash flow | −32.1 | −55.6 | −81.9 |
| Depreciation & amortisation | 0.2 | 0.2 | 0.2 |
| Stock-based compensation | 2.0 | 5.2 | 8.7 |
| Fiscal year | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Return on equityBlank when equity is negative | – | −24.1% | −23.6% |
| ROCEEBIT ÷ (assets − current liabilities) | −44.0% | −26.5% | −26.5% |
| Cash conversion (CFO ÷ net income) | 0.98x | 0.88x | 0.92x |
| Current ratio | 21.3x | 24.2x | 24.6x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.